Bastiano Sanna - 07 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
07 Apr 2022
Net transactions value
-$154,935
Form type
4
Filing time
08 Apr 2022, 16:34:51 UTC
Previous filing
06 Apr 2022
Next filing
03 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $56,245 -204 -0.47% $275.71 43,139 07 Apr 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $90,380 -327 -0.76% $276.39 42,812 07 Apr 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale $8,311 -30 -0.07% $277.02 42,782 07 Apr 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $275.71 (range $275.00 to $275.95).
F4 Open market sales reported on this line occurred at a weighted average price of $276.39 (range $276.00 to $276.78).